The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

References

• Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–70.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:1059–64.
   PubMed Web of Science ®Google Scholar
• Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J. 2007;28:692–8.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2002;23:1771–9.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–9.
   PubMed Web of Science ®Google Scholar
• Bjorklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, et al. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J. 2004;148:566–73.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review. Semin Thromb Hemost. 2014;40:621–33.
   PubMed Web of Science ®Google Scholar
• Ollivier V, Wang J, Manly D, Machlus KR, Wolberg AS, Jandrot-Perrus M, et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2010;125:90–6.
   PubMed Web of Science ®Google Scholar
• SWEDEHEART Annual Report 2011 (English edition). Available from: http://www.ucr.uu.se/swedeheart/index.php/dokument-sh/arsrapporter.
   Google Scholar
• Galvani M, Ferrini D, Ottani F, Eisenberg PR. Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. Int J Cardiol. 1999;68(Suppl1):S55–S61.
   Web of Science ®Google Scholar
• Halvorsen S, Seljeflot I, Weiss T, Bohmer E, Arnesen H. Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy. Thromb Res. 2012;130:495–500.
   PubMed Web of Science ®Google Scholar
• Krupinski J, Turu MM, Font MA, Ahmed N, Sullivan M, Rubio F, et al. Increased tissue factor, MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. Vasc Health Risk Manag. 2007;3:405–12.
   PubMedGoogle Scholar
• Teunissen PF, Tijssen R, van Montfoort ML, Robbers LF, de Waard GA, van de Ven PM, et al. Kinetics of coagulation in ST-elevation myocardial infarction following successful primary percutaneous coronary intervention. Thromb Res. 2016;137:64–71.
   PubMed Web of Science ®Google Scholar
• Bratseth V, Pettersen AA, Opstad TB, Arnesen H, Seljeflot I. Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment. Thromb J. 2012;10:12.
   PubMedGoogle Scholar
• Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993;14:205–12.
   PubMed Web of Science ®Google Scholar
• Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030–8.
   PubMed Web of Science ®Google Scholar
• Minami Y, Haruki S, Jujo K, Itani R, Shimazaki K, Arashi H, et al. Elevated D-dimer levels predict an adverse outcome in hospitalized patients with acute decompensated heart failure. Int J Cardiol. 2016;204:42–4.
   PubMed Web of Science ®Google Scholar
• Kikkert WJ, Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, et al. Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. J Thromb Thrombolysis. 2013;35:200–8.
   PubMed Web of Science ®Google Scholar
• Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost. 2012;38:673–82.
   PubMed Web of Science ®Google Scholar
• Lind M, Boman K, Johansson L, Nilsson TK, Jarvholm LS, Jansson JH. D-dimer predicts major bleeding, cardiovascular events and all-cause mortality during warfarin treatment. Clin Biochem. 2014;47:570–3.
   PubMed Web of Science ®Google Scholar
• Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, et al. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J. 1999;20:1493–502.
   PubMed Web of Science ®Google Scholar
• Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011;105:181–9.
   PubMed Web of Science ®Google Scholar
• Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147–52.
   PubMed Web of Science ®Google Scholar
• Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res. 2009;123:573–9.
   PubMed Web of Science ®Google Scholar
• Smid M, Dielis AW, Winkens M, Spronk HM, van Oerle R, Hamulyak K, et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost. 2011;9:450–6.
   PubMed Web of Science ®Google Scholar
• Kalz J, ten Cate H, Spronk HM. Thrombin generation and atherosclerosis. J Thromb Thrombolysis. 2014;37:45–55.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Heeneman S, Kilinc E, Kassak P, Van Oerle R, Winckers K, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122:821–30.
   PubMed Web of Science ®Google Scholar
• Loeffen R, Winckers K, Ford I, Jukema JW, Robertson M, Stott DJ, et al. Associations between thrombin generation and the risk of cardiovascular disease in elderly patients: results from the PROSPER Study. J Gerontol A Biol Sci Med Sci. 2015;70:982–8.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Koppensteiner R, Ay C, Panzer S. Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. Eur J Clin Invest. 2014;44:319–24.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Johanson P, Held C, Svennblad B, Lindback J, Wallentin L, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA. 2011;305:1677–84.
   PubMed Web of Science ®Google Scholar
• Chung SC, Sundstrom J, Gale CP, James S, Deanfield J, Wallentin L, et al. Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. BMJ. 2015;351:h3913.
   PubMed Web of Science ®Google Scholar
• Cimenti C, Koestenberger M, Leschnik B, Haidl H, Muntean W. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Thromb Res. 2007;119:361–7.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost. 2007;5:955–62.
   PubMed Web of Science ®Google Scholar